Human umbilical cord blood mononuclear cells transfected with dual cassette plasmids(vegf + neurotrophic factor) for the treatment of amyotrophic lateral sclerosis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

To increase the viability of neural cells in neurodegenerative
diseases, after neurotraumas and ischemic strokes the
most important neurotrophic and neuroprotective factors,
which can be used as therapeutic agents were identified
in long-term studies in vitro and in vivo. These include
brain-derived neurotrophic factor (BDNF), glial-derived
neurotrophic factor (GDNF), insulin-like growth factor (IGF)
and vascular endothelial growth factor (VEGF). One of the
promising ways of the delivery of supporting neuron survival
factors is considered to be transplantation of genetically
modified cells overexpressing recombinant therapeutic
genes. This article describes generation of cellular delivery
vectors of therapeutic genes - human umbilical cord blood
mononuclear cells genetically modified by dual cassette
plasmids, expressing two therapeutic genes. Efficiency of
transgene expression was confirmed in vitro using RT-PCR.
Analysis of survival, migration, and phenotype of genetically
modified cells was performed 2 weeks after transplantation
into transgenic mice with amyotrophic lateral sclerosis
phenotype.

About the authors

N V Kudryashova

Кazan (Volga region) Federal University, Kazan

Кazan (Volga region) Federal University, Kazan

D S Guseva

Кazan State Medical University, Kazan

Кazan State Medical University, Kazan

I I Salafutdinov

Кazan (Volga region) Federal University, Kazan

Кazan (Volga region) Federal University, Kazan

F V Bashirov

Кazan (Volga region) Federal University, Kazan

Кazan (Volga region) Federal University, Kazan

A P Kiiasov

Кazan (Volga region) Federal University, Kazan

Кazan (Volga region) Federal University, Kazan

A A Rizvanov

Кazan (Volga region) Federal University, Kazan

Кazan (Volga region) Federal University, Kazan

R R Islamov

Кazan State Medical University, Kazan

Кazan State Medical University, Kazan

References

  1. Ризванов А.А., Гусева Д.С., Салафутдинов И.И. и др. Докли- нические исследования терапии бокового амиотрофического скле- роза с помощью генетически модифицированных мононуклеарных клеток крови пуповины. Клеточная Трансплантология и Тканевая Инженерия 2012; 7(2): 56-63.
  2. Исламов Р.Р., Ризванов А.А., Киясов А.П. Боковой амиотро- фический склероз: стратегия генно-клеточной терапи. Неврологи- ческий вестник 2008; 40(4): 91-101.
  3. Rizvanov A.A., Guseva D.S., Salafutdinov I.I. et al., Genetically modified human umbilical cord blood cells expressing vascular endothelial growth factor and fibroblast growth factor 2 differentiate into glial cells after transplantation into amyotrophic lateral sclerosis transgenic mice. Exp. Biol. Med. 2011; 236(1): 91-8.
  4. Салафутдинов И.И., Шафигуллина А.К., Ялвач M.Э. и др. Эффект одновременной экспрессии различных изоформ фактора роста эндотелия сосудов VEGF и основного фактора роста фибро- бластов FGF2 на пролиферацию эндотелиальных клеток пупочной вены человека HUVEC. Клеточная Трансплантология и Тканевая Ин- женерия 2010; 5(2): 62-7.
  5. Ризванов А.А., Гусева Д.С., Салафутдинов И.И. и др. Генно- клеточная терапия бокового амиотрофического склероза монону- клеарными клетками пуповинной крови человека, трансфицирован- ными генами нейронной молекулы адгезии L1CAM и сосудистого эндотелиального фактора роста VEGF. Клеточная трансплантология и тканевая инженерия 2010; 5(4): 55-65.
  6. Szulc J., Wiznerowicz M., Sauvain M.O. et al. A versatile tool for conditional gene expression and knockdown. Nat. Methods. 2006; 3(2): 109-16.
  7. Hawley T.S., Hawley R.G., Totowa N.J. Flow Cytometry Protocols 2ed. Methods in Molecular Biology: Humana Press; 2004: 424.
  8. Rizvanov A.A., Kiyasov A.P., Gaziziov I.M. et al. Human umbilical cord blood cells transfected with VEGF and L(1)CAM do not differentiate into neurons but transform into vascular endothelial cells and secrete neuro-trophic factors to support neuro-genesis-a novel approach in stem cell therapy. Neurochem. Int. 2008; 53(6): 389-94.
  9. Chintalgattu V., Nair D.M., Katwa L.C. Cardiac myofibroblasts: a novel source of vascular endothelial growth factor (VEGF) and its receptors Flt-1 and KDR. J. Mol. Cell Cardiol. 2003; 35(3): 277-86.
  10. Jiao Y., Sun Z., Lee T. et al. A simple and sensitive antigen retrieval method for free-floating and slide-mounted tissue sections.
  11. J. Neurosci. Methods. 1999; 93(2): 149-62.
  12. Lunn J.S., Hefferan M.P., Marsala M. et al. Stem cells: comprehensive treatments for amyotrophic lateral sclerosis in conjunction with growth factor delivery. Growth Factors 2009; 27(3): 133-40.
  13. Hester M.E., Foust K.D., Kaspar R.W. et al. AAV as a gene transfer vector for the treatment of neurological disorders: novel treatment thoughts for ALS. Curr. Gene Ther. 2009; 9(5): 428-33.

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2012 Eco-Vector



СМИ зарегистрировано Федеральной службой по надзору в сфере связи, информационных технологий и массовых коммуникаций (Роскомнадзор).
Регистрационный номер и дата принятия решения о регистрации СМИ: 

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies